GDNF: aiming to regrow dopamine cells to stop or even reverse Parkinson’s

For a decade we have supported the development of resarch involving Glial Derived Neurotrophic Factor (GDNF), a natural brain growth molecule thought to be important for cell regrowth in Parkinson's. We have supported the development of the new convection enhanced delivery mechanism to deliver this large sticky molecule with pin-point accuracy into the brain. The trial is nearing completion in Bristol and in-depth analysis of the data is underway.

This trial has been an excellent collaboration between the inspirational team at Southmead Hospital Bristol, MedGenesis, Michael J Fox Foundation, Parkinson's UK and The Cure Parkinson's Trust.

We would also like to thank the following benefactors for their generous support of this trial:

ICAP, The Annett Trust, The Batchworth Trust, The Chapman Charitable Trust, The Christopher Laing Foundation, D D McPhail Charitable Settlement, Derek Stewart Charitable Trust, The Florian Charitable Trust, The Greenmount College Sports Fund, The Hoover Foundation, The Hospital Saturday Fund, The Inman Charity, John Kirkhope Young Endowment Fund, The Lady Eileen Joseph Foundation, Martin Connell Charitable Trust, The Misses Barrie Charitable Trust, Rosetrees Trust, The Sir James Roll Charitable Trust, Sir Samuel Scott of Yews Trust, The Souter Charitable Trust, Stadium Charitable Trust, The Stafford Trust, The Wogen Anniversary Trust, The Worshipful Company of Gold and Silver Wyre Drawers, Henry Lumley Charitable Trust, Ibbett Trust, JK Stirrup Charitable Trust.